{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:26:23Z","timestamp":1791379583554,"version":"4.3.3"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41397-021-00255-3","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:04:14Z","timestamp":1642377854000},"page":"39-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of ITPA gene polymorphisms with adverse effects of AZA\/6-MP administration: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"22","author":[{"given":"Evaggelia","family":"Barba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota I.","family":"Kontou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8991-8712","authenticated-orcid":false,"given":"Ioannis","family":"Michalopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4935-2325","authenticated-orcid":false,"given":"Pantelis G.","family":"Bagos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3982-3250","authenticated-orcid":false,"given":"Georgia G.","family":"Braliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"255_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/lt.20377","volume":"11","author":"DP Breen","year":"2005","unstructured":"Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl. 2005;11:826\u201333.","journal-title":"Liver Transpl."},{"key":"255_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166\u201378.","journal-title":"N Engl J Med."},{"key":"255_CR3","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030\u201343.","journal-title":"Lancet."},{"key":"255_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00003088-200746030-00001","volume":"46","author":"A Teml","year":"2007","unstructured":"Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinetics. 2007;46:187\u2013208.","journal-title":"Clin Pharmacokinetics."},{"key":"255_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/gut.34.8.1081","volume":"34","author":"WR Connell","year":"1993","unstructured":"Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081\u20135.","journal-title":"Gut."},{"key":"255_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/j.1572-0241.2003.07459.x","volume":"98","author":"A Floyd","year":"2003","unstructured":"Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol. 2003;98:1305\u20138.","journal-title":"Am J Gastroenterol"},{"key":"255_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/apt.13559","volume":"43","author":"W Moon","year":"2016","unstructured":"Moon W, Loftus EV Jr. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Alimentary Pharmacol Therapeut. 2016;43:863\u201383.","journal-title":"Alimentary Pharmacol Therapeut."},{"key":"255_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/00008571-200208000-00003","volume":"12","author":"M Schwab","year":"2002","unstructured":"Schwab M, Schaffeler E, Marx C, Fischer C, Lang T, Behrens C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12:429\u201336.","journal-title":"Pharmacogenetics."},{"key":"255_CR9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1365-2036.2008.03788.x","volume":"28","author":"A Ansari","year":"2008","unstructured":"Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Alimentary Pharmacol Therapeut. 2008;28:973\u201383.","journal-title":"Alimentary Pharmacol Therapeut."},{"key":"255_CR10","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1081\/NCN-200027639","volume":"23","author":"AM Marinaki","year":"2004","unstructured":"Marinaki AM, Duley JA, Arenas M, Ansari A, Sumi S, Lewis CM, et al. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids. 2004;23:1393\u20137.","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"key":"255_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","volume":"19","author":"M Chaparro","year":"2013","unstructured":"Chaparro M, Ordas I, Cabre E, Garcia-Sanchez V, Bastida G, Penalva M, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404\u201310.","journal-title":"Inflamm Bowel Dis."},{"key":"255_CR12","first-page":"173","volume":"32","author":"A Watanabe","year":"1978","unstructured":"Watanabe A, Hobara N, Nagashima H. Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine. Acta Med Okayama. 1978;32:173\u20139.","journal-title":"Acta Med Okayama."},{"key":"255_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2036.2005.02520.x","volume":"22","author":"CA Siegel","year":"2005","unstructured":"Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Alimentary Pharmacol Therapeut. 2005;22:1\u201316.","journal-title":"Alimentary Pharmacol Therapeut."},{"key":"255_CR14","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2217\/PGS.15.62","volume":"16","author":"MS Hareedy","year":"2015","unstructured":"Hareedy MS, El Desoky ES, Woillard JB, Thabet RH, Ali AM, Marquet P, et al. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015;16:1119\u201334.","journal-title":"Pharmacogenomics."},{"key":"255_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00008571-200403000-00006","volume":"14","author":"AM Marinaki","year":"2004","unstructured":"Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004;14:181\u20137.","journal-title":"Pharmacogenetics."},{"key":"255_CR16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/JCI16432","volume":"111","author":"I Tiede","year":"2003","unstructured":"Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Investig. 2003;111:1133\u201345.","journal-title":"J Clin Investig."},{"key":"255_CR17","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1016\/0006-2952(86)90623-4","volume":"35","author":"CR Fairchild","year":"1986","unstructured":"Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochemical Pharmacol. 1986;35:3533\u201341.","journal-title":"Biochemical Pharmacol."},{"key":"255_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/gut.51.2.143","volume":"51","author":"L Lennard","year":"2002","unstructured":"Lennard L. TPMT in the treatment of Crohn\u2019s disease with azathioprine. Gut. 2002;51:143\u20136.","journal-title":"Gut."},{"key":"255_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2036.2005.02343.x","volume":"21","author":"FN Aberra","year":"2005","unstructured":"Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Alimentary Pharmacol Therapeut. 2005;21:307\u201319.","journal-title":"Alimentary Pharmacol Therapeut."},{"key":"255_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/01.ftd.0000179839.71138.6d","volume":"28","author":"LJ Derijks","year":"2006","unstructured":"Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, et al. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Therapeutic Drug Monit. 2006;28:45\u201350.","journal-title":"Therapeutic Drug Monit."},{"key":"255_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/clpt.2008.154","volume":"85","author":"G Stocco","year":"2009","unstructured":"Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Therapeut. 2009;85:164\u201372.","journal-title":"Clin Pharmacol Therapeut."},{"key":"255_CR22","doi-asserted-by":"publisher","first-page":"13575","DOI":"10.18632\/oncotarget.14594","volume":"8","author":"D Yin","year":"2017","unstructured":"Yin D, Xia X, Zhang J, Zhang S, Liao F, Zhang G, et al. Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose. Oncotarget. 2017;8:13575\u201385.","journal-title":"Oncotarget."},{"key":"255_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11845-017-1608-x","volume":"187","author":"AL Zhang","year":"2018","unstructured":"Zhang AL, Yang J, Wang H, Lu JL, Tang S, Zhang XJ. Association of NUDT15 c.415C>T allele and thiopurine-induced leukocytopenia in Asians: a systematic review and meta-analysis. Ir J Med Sci. 2018;187:145\u201353.","journal-title":"Ir J Med Sci."},{"key":"255_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/jcph.2","volume":"53","author":"OH Nielsen","year":"2013","unstructured":"Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013;53:575\u201388.","journal-title":"J Clin Pharmacol."},{"key":"255_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cpt.1344","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Therapeutic. 2019;105:5.","journal-title":"Clin Pharmacol Therapeutic."},{"key":"255_CR26","first-page":"399","volume":"53","author":"JP Gisbert","year":"2006","unstructured":"Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepato-Gastroenterol. 2006;53:399\u2013404.","journal-title":"Hepato-Gastroenterol."},{"key":"255_CR27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0016-5085(00)70354-4","volume":"118","author":"JF Colombel","year":"2000","unstructured":"Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn\u2019s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025\u201330.","journal-title":"Gastroenterology."},{"key":"255_CR28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.25485","volume":"94","author":"S Koutsilieri","year":"2019","unstructured":"Koutsilieri S, Caudle KE, Alzghari SK, Monte AA, Relling MV, Patrinos GP. Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango. Am J Hematol. 2019;94:737\u201340. Wiley-Liss Inc","journal-title":"Am J Hematol"},{"key":"255_CR29","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.leukres.2015.06.016","volume":"39","author":"F Azimi","year":"2015","unstructured":"Azimi F, Mortazavi Y, Alavi S, Khalili M, Ramazani A. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects. Leuk Res. 2015;39:1048\u201354.","journal-title":"Leuk Res."},{"key":"255_CR30","first-page":"4552","volume":"7","author":"X Ma","year":"2014","unstructured":"Ma X, Zheng J, Jin M, Li W, Gao C, Zhang D, et al. Inosine triphosphate pyrophosphohydrolase (ITPA) polymorphic sequence variants in Chinese ALL children and possible association with mercaptopurine related toxicity. Int J Clin Exp Pathol. 2014;7:4552\u20136.","journal-title":"Int J Clin Exp Pathol."},{"key":"255_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00535-008-2307-1","volume":"44","author":"K Uchiyama","year":"2009","unstructured":"Uchiyama K, Nakamura M, Kubota T, Yamane T, Fujise K, Tajiri H. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine\/6-mercaptopurine treatment. J Gastroenterol. 2009;44:197\u2013203.","journal-title":"J Gastroenterol."},{"key":"255_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cgh.2005.10.019","volume":"4","author":"Z Zelinkova","year":"2006","unstructured":"Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4:44\u20139.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"255_CR33","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1074\/jbc.M609838200","volume":"282","author":"P Stenmark","year":"2007","unstructured":"Stenmark P, Kursula P, Flodin S, Gr\u00e4slund S, Landry R, Nordlund P, et al. Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T. J Biol Chem. 2007;282:3182\u20137.","journal-title":"J Biol Chem."},{"key":"255_CR34","doi-asserted-by":"publisher","first-page":"18695","DOI":"10.1074\/jbc.M011084200","volume":"276","author":"S Lin","year":"2001","unstructured":"Lin S, McLennan AG, Ying K, Wang Z, Gu S, Jin H, et al. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the itpa gene. J Biol Chem. 2001;276:18695\u2013701.","journal-title":"J Biol Chem."},{"key":"255_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1373\/clinchem.2005.059501","volume":"52","author":"M Shipkova","year":"2006","unstructured":"Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of Erythrocyte Inosine Triphosphate Pyrophosphohydrolase (ITPA) Activity by HPLC and Correlation of ITPA Genotype-Phenotype in a Caucasian Population. Clin Chem. 2006;52:240\u201347.","journal-title":"Clin Chem"},{"key":"255_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00439-002-0798-z","volume":"111","author":"S Sumi","year":"2002","unstructured":"Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002;111:360\u20137.","journal-title":"Hum Genet"},{"key":"255_CR37","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.2337\/diabetes.52.12.2984","volume":"52","author":"H Biebermann","year":"2003","unstructured":"Biebermann H, Krude H, Elsner A, Chubanov V, Gudermann T, Gr\u00fcters A. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes. 2003;52:2984\u201388.","journal-title":"Diabetes."},{"key":"255_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1877-1173(09)89003-0","volume":"89","author":"GN Hendy","year":"2009","unstructured":"Hendy GN, Geoffrey N, Vito Guarnieri, Lucie Canaff. Chapter 3 calcium-sensing receptor and associated diseases. Prog Mol Biol Transl Sci. 2009;89:31\u201395.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"255_CR39","doi-asserted-by":"publisher","first-page":"E94","DOI":"10.1097\/MPH.0000000000001707","volume":"42","author":"TW Kouwenberg","year":"2020","unstructured":"Kouwenberg TW, van den Bosch BJC, Bierau J, Te Loo DMWM, Coenen MJH, Hagleitner MM. Dosage of 6-mercaptopurine in relation to genetic TPMT and ITPA variants: toward individualized pediatric acute lymphoblastic leukemia maintenance treatment. J Pediatr Hematol\/Oncol. 2020;42:E94\u201397.","journal-title":"J Pediatr Hematol\/Oncol"},{"key":"255_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1365-2036.2007.03412.x","volume":"26","author":"JM Van Dieren","year":"2007","unstructured":"Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Van der Woude CJ. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Alimentary Pharmacol Therapeut. 2007;26:643\u201352.","journal-title":"Alimentary Pharmacol Therapeut."},{"key":"255_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-127-5-199709010-00008","volume":"127","author":"C Counsell","year":"1997","unstructured":"Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med. 1997;127:380\u20137. American College of Physicians","journal-title":"Ann Intern Med."},{"key":"255_CR42","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"255_CR43","first-page":"MR000010","volume":"18","author":"S Hopewell","year":"2007","unstructured":"Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev. 2007;18:MR000010.","journal-title":"Cochrane Database Syst Rev."},{"key":"255_CR44","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008\u201312.","journal-title":"JAMA."},{"key":"255_CR45","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"255_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177\u201388.","journal-title":"Controlled Clin Trials"},{"key":"255_CR47","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ."},{"key":"255_CR48","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u2013101.","journal-title":"Biometrics."},{"key":"255_CR49","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ."},{"key":"255_CR50","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jclinepi.2008.12.008","volume":"62","author":"PG Bagos","year":"2009","unstructured":"Bagos PG, Nikolopoulos GK. Generalized least squares for assessing trends in cumulative meta-analysis with applications in genetic epidemiology. J Clin Epidemiol. 2009;62:1037\u201344.","journal-title":"J Clin Epidemiol"},{"key":"255_CR51","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2105\/AJPH.86.5.726","volume":"86","author":"M Aickin","year":"1996","unstructured":"Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health. 1996;86:726\u20138.","journal-title":"Am J Public Health."},{"key":"255_CR52","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65\u201370.","journal-title":"Scand J Stat"},{"key":"255_CR53","first-page":"626","volume":"62","author":"Z \u0160id\u00e1k","year":"1967","unstructured":"\u0160id\u00e1k Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc. 1967;62:626\u201333.","journal-title":"J Am Stat Assoc."},{"key":"255_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1348\/000711002159680","volume":"55","author":"HJ Keselman","year":"2002","unstructured":"Keselman HJ, Cribbie R, Holland B. Controlling the rate of Type I error over a large set of statistical tests. Br J Math Stat Psychol. 2002;55:27\u201339.","journal-title":"Br J Math Stat Psychol"},{"key":"255_CR55","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jpeds.2019.09.024","volume":"216","author":"M Wahlund","year":"2020","unstructured":"Wahlund M, Nilsson A, Kahlin AZ, Broliden K, Myrberg IH, Appell ML, et al. The role of TPMT, ITPA, and NUDT15 variants during mercaptopurine treatment of swedish pediatric patients with acute lymphoblastic leukemia. J Pediatr. 2020;216:150\u2013.e1.","journal-title":"J Pediatr."},{"key":"255_CR56","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/j.1365-2036.2006.02853.x","volume":"23","author":"L De Ridder","year":"2006","unstructured":"De Ridder L, Van Dieren JM, Van Deventer HJ, Stokkers PC, Van der Woude JC, Van, et al. Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Alimentary Pharmacol Therapeut. 2006;23:1137\u201341.","journal-title":"Alimentary Pharmacol Therapeut."},{"key":"255_CR57","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00228-009-0630-y","volume":"65","author":"M Kurzawski","year":"2009","unstructured":"Kurzawski M, Dziewanowski K, Lener A, Drozdzik M. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol. 2009;65:533\u201340.","journal-title":"Eur J Clin Pharmacol"},{"key":"255_CR58","doi-asserted-by":"publisher","first-page":"e0137798","DOI":"10.1371\/journal.pone.0137798","volume":"10","author":"S Odahara","year":"2015","unstructured":"Odahara S, Uchiyama K, Kubota T, Ito Z, Takami S, Kobayashi H, et al. A prospective study evaluating metabolic capacity of thiopurine and associated adverse reactions in Japanese patients with inflammatory bowel disease (IBD). PloS One. 2015;10:e0137798.","journal-title":"PloS One."},{"key":"255_CR59","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1365-2036.2007.03421.x","volume":"26","author":"O Palmieri","year":"2007","unstructured":"Palmieri O, Latiano A, Bossa F, Vecchi M, D\u2019Inca R, Guagnozzi D, et al. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines\u2019 toxicity and efficacy. Alimentary Pharmacol Therapeut. 2007;26:737\u201345.","journal-title":"Alimentary Pharmacol Therapeut."},{"key":"255_CR60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.advms.2015.09.008","volume":"61","author":"R Steponaitiene","year":"2016","unstructured":"Steponaitiene R, Kupcinskas J, Survilaite S, Varkalaite G, Jonaitis L, Kiudelis G, et al. TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: prevalence and azathioprine-related side effects. Adv Med Sci. 2016;61:135\u201340.","journal-title":"Adv Med Sci."},{"key":"255_CR61","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1097\/MCG.0b013e3181d6baf5","volume":"44","author":"JH Kim","year":"2010","unstructured":"Kim JH, Cheon JH, Hong SS, Eun CS, Byeon JS, Hong SY, et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol. 2010;44:e242\u20138.","journal-title":"J Clin Gastroenterol"},{"key":"255_CR62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/tpj.2017.12","volume":"18","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Nakadate H, Kondoh K, Nakamura K, Koh K, Manabe A. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2018;18:275\u201380.","journal-title":"Pharmacogenomics J"},{"key":"255_CR63","first-page":"1664","volume":"54","author":"JM van Dieren","year":"2005","unstructured":"van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, van der Woude CJ. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut. 2005;54:1664.","journal-title":"Gut."},{"key":"255_CR64","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/00008571-200411000-00010","volume":"14","author":"RB Gearry","year":"2004","unstructured":"Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics. 2004;14:779\u201381.","journal-title":"Pharmacogenetics."},{"key":"255_CR65","first-page":"247","volume":"20","author":"W Zabala-Fernandez","year":"2011","unstructured":"Zabala-Fernandez W, Barreiro-de Acosta M, Echarri A, Carpio D, Lorenzo A, Castro J, et al. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. J Gastrointest Liver Dis. 2011;20:247\u201353.","journal-title":"J Gastrointest Liver Dis."},{"key":"255_CR66","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/gut.2005.074930","volume":"55","author":"U Hindorf","year":"2006","unstructured":"Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006;55:1423\u201331.","journal-title":"Gut."},{"key":"255_CR67","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1365-2125.2008.03248.x","volume":"66","author":"AF Hawwa","year":"2008","unstructured":"Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, McCarthy A, Dempsey S, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008;66:517\u201328.","journal-title":"Br J Clin Pharmacol."},{"key":"255_CR68","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1472-8206.2009.00770.x","volume":"24","author":"H Xiong","year":"2010","unstructured":"Xiong H, Xin HW, Wu XC, Li Q, Xiong L, Yu AR. Association between inosine triphosphate pyrophosphohydrolase deficiency and azathioprine-related adverse drug reactions in the Chinese kidney transplant recipients. Fundamental Clin Pharmacol. 2010;24:393\u2013400.","journal-title":"Fundamental Clin Pharmacol"},{"key":"255_CR69","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/tpj.2014.74","volume":"15","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Manabe A, Fukushima H, Suzuki R, Nakadate H, Kondoh K, et al. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15:380\u20134.","journal-title":"Pharmacogenomics J."},{"key":"255_CR70","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1373\/clinchem.2005.057158","volume":"51","author":"N von Ahsen","year":"2005","unstructured":"von Ahsen N, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, et al. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem. 2005;51:2282\u20138.","journal-title":"Clin Chem"},{"key":"255_CR71","first-page":"e26","volume":"23","author":"B Al-Judaibi","year":"2016","unstructured":"Al-Judaibi B, Schwarz UI, Huda N, Dresser GK, Gregor JC, Ponich T, et al. Genetic predictors of azathioprine toxicity and clinical response in patients with inflammatory bowel disease. J Popul Therapeutics Clin Pharmacol. 2016;23:e26\u201336.","journal-title":"J Popul Therapeutics Clin Pharmacol."},{"key":"255_CR72","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ped.12682","volume":"57","author":"R Suzuki","year":"2015","unstructured":"Suzuki R, Fukushima H, Noguchi E, Tsuchida M, Kiyokawa N, Koike K, et al. Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia. Pediatr Int. 2015;57:572\u20137.","journal-title":"Pediatr Int"},{"key":"255_CR73","doi-asserted-by":"publisher","first-page":"e45558","DOI":"10.1371\/journal.pone.0045558","volume":"7","author":"H Kim","year":"2012","unstructured":"Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y, et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS One. 2012;7:e45558.","journal-title":"PLoS One."},{"key":"255_CR74","doi-asserted-by":"publisher","first-page":"e109551","DOI":"10.1371\/journal.pone.0109551","volume":"9","author":"A Smid","year":"2014","unstructured":"Smid A, Karas-Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I. Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapy. PLoS One. 2014;9:e109551.","journal-title":"PLoS One."},{"key":"255_CR75","first-page":"22","volume":"72","author":"A Tsuchiya","year":"2017","unstructured":"Tsuchiya A, Aomori T, Sakamoto M, Takeuchi A, Suzuki S, Jibiki A, et al. Effect of genetic polymorphisms of azathioprine-metabolizing enzymes on response to rheumatoid arthritis treatment. Pharmazie. 2017;72:22\u201328.","journal-title":"Pharmazie."},{"key":"255_CR76","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/1346-8138.14588","volume":"45","author":"M Kishibe","year":"2018","unstructured":"Kishibe M, Nozaki H, Fujii M, Iinuma S, Ohtsubo S, Igawa S, et al. Severe thiopurine-induced leukocytopenia and hair loss in Japanese patients with defective NUDT15 variant: Retrospective case-control study. J Dermatol. 2018;45:1160\u20135.","journal-title":"J Dermatol."},{"key":"255_CR77","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2217\/14622416.8.9.1221","volume":"8","author":"J Bierau","year":"2007","unstructured":"Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics. 2007;8:1221\u20131228.","journal-title":"Pharmacogenomics."},{"key":"255_CR78","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.hoc.2019.01.004","volume":"33","author":"K Walkovich","year":"2019","unstructured":"Walkovich K, Connelly JA. Congenital neutropenia and rare functional phagocyte disorders in children. Hematol\/Oncol Clin North Am. 2019;33:533\u201351. W.B. Saunders","journal-title":"Hematol\/Oncol Clin North Am."},{"key":"255_CR79","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/00498254.2019.1688424","volume":"50","author":"AM Marinaki","year":"2020","unstructured":"Marinaki AM, Arenas-Hernandez M. Reducing risk in thiopurine therapy. Xenobiotica. 2020;50:101\u20139. Taylor and Francis Ltd","journal-title":"Xenobiotica."},{"key":"255_CR80","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/ng1194-303","volume":"8","author":"MR Pollak","year":"1994","unstructured":"Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, et al. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet. 1994;8:303\u20137.","journal-title":"Nat Genet."},{"key":"255_CR81","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s100380200095","volume":"47","author":"H Cao","year":"2002","unstructured":"Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet. 2002;47:620\u201322.","journal-title":"J Hum Genet"},{"key":"255_CR82","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10038-004-0183-y","volume":"49","author":"S Marsh","year":"2004","unstructured":"Marsh S, King CR, Ahluwalia R, McLeod HL. Distribution of ITPA P32T Alleles in Multiple World Populations. J Hum Genet. 2004;49:579\u201381.","journal-title":"J Hum Genet."},{"key":"255_CR83","first-page":"12","volume":"8","author":"K Lakiotaki","year":"2017","unstructured":"Lakiotaki K, Kanterakis A, Kartsaki E, Katsila T, Patrinos GP, Potamias G. Exploring public genomics data for population pharmacogenomics. PLoS One. 2017;8:12.","journal-title":"PLoS One."},{"key":"255_CR84","doi-asserted-by":"crossref","unstructured":"Katara P, Yadav A Pharmacogenes (PGx-genes): Current understanding and future directions. Gene. Nov, 2019;718. Elsevier B.V.","DOI":"10.1016\/j.gene.2019.144050"},{"key":"255_CR85","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2217\/pgs-2017-0005","volume":"18","author":"ZN Al-Mahayri","year":"2017","unstructured":"Al-Mahayri ZN, Patrinos GP, Ali BR. Pharmacogenomics in pediatric acute lymphoblastic leukemia: Promises and limitations. Pharmacogenomics. 2017;18:687\u201399. Future Medicine Ltd","journal-title":"Pharmacogenomics."},{"key":"255_CR86","doi-asserted-by":"crossref","unstructured":"Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, Mitropoulou C, Patrinos GP. Application of economic evaluation to assess feasibility for reimbursement of genomic testing as part of personalized medicine interventions. Front Pharmacol. 2019;10:830.","DOI":"10.3389\/fphar.2019.00830"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00255-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00255-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00255-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T22:04:29Z","timestamp":1700085869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-021-00255-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1038\/s41397-021-00255-3","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"10 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}